NO20006255L - Crystalline efavirenz - Google Patents

Crystalline efavirenz

Info

Publication number
NO20006255L
NO20006255L NO20006255A NO20006255A NO20006255L NO 20006255 L NO20006255 L NO 20006255L NO 20006255 A NO20006255 A NO 20006255A NO 20006255 A NO20006255 A NO 20006255A NO 20006255 L NO20006255 L NO 20006255L
Authority
NO
Norway
Prior art keywords
crystalline efavirenz
efavirenz
crystalline
Prior art date
Application number
NO20006255A
Other languages
Norwegian (no)
Other versions
NO20006255D0 (en
Inventor
Lilian Alicia Radesca
Michael B Maurin
Shelley R Rabel
James R Moore
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006255(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20006255D0 publication Critical patent/NO20006255D0/en
Publication of NO20006255L publication Critical patent/NO20006255L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20006255A 1998-06-11 2000-12-08 Crystalline efavirenz NO20006255L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11
PCT/US1999/013199 WO1999064405A1 (en) 1998-06-11 1999-06-10 Crystalline efavirenz

Publications (2)

Publication Number Publication Date
NO20006255D0 NO20006255D0 (en) 2000-12-08
NO20006255L true NO20006255L (en) 2001-02-12

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006255A NO20006255L (en) 1998-06-11 2000-12-08 Crystalline efavirenz

Country Status (21)

Country Link
EP (1) EP1086087A1 (en)
JP (1) JP2002517487A (en)
CN (1) CN1307568A (en)
AR (3) AR018670A1 (en)
AU (1) AU758114C (en)
BR (1) BR9911523A (en)
CA (1) CA2333550A1 (en)
EE (1) EE05547B1 (en)
HR (1) HRP990182A2 (en)
HU (1) HUP0103819A3 (en)
IL (1) IL139793A (en)
MY (1) MY126450A (en)
NO (1) NO20006255L (en)
NZ (1) NZ507713A (en)
PL (1) PL198504B1 (en)
SG (3) SG111980A1 (en)
SK (1) SK18182000A3 (en)
TW (1) TWI235152B (en)
UA (1) UA74324C2 (en)
WO (1) WO1999064405A1 (en)
ZA (1) ZA200006173B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
US7205402B2 (en) * 2004-09-02 2007-04-17 Bristol-Myers Squibb Company Synthesis of a benzoxazinone
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz
CA2712574C (en) 2008-02-04 2014-01-07 Pfizer Limited Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (en) 2009-09-16 2011-03-31 Archimica Gmbh Salts of 6-chloro-4- (cyclopropylethynyl) -1,4-dihydro-4- (trifluoromethyl) -2H-3,1-benzoxazin-2-one and their synthesis, purification and use as precursors of efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (en) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 Prepare the method for efavirenz I type crystallization
CN102924398B (en) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 For removing the method for the corresponding isomer of efavirenz
US9468646B2 (en) 2013-01-23 2016-10-18 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
CN105037175B (en) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 Method of improving optical purity of efavirenz intermediate
CN105001101B (en) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 A kind of synthetic method of the trifluoroacetyl aniline hydrate hydrochloride of 4 chlorine 2
CN108947855B (en) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 Synthesis method of efavirenz key intermediate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
CA2260922A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
ES2203790T3 (en) * 1996-10-02 2004-04-16 Bristol-Myers Squibb Pharma Company 1,4-DIHIDRO-2H-3,1-BENZOXACIN-2-ONAS 4,4-USEFUL DISPOSED AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND INTERMEDIATES AND PROCEDURES FOR PREPARATION.
HU229087B1 (en) * 1997-02-05 2013-07-29 Merck Sharp & Dohme Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Also Published As

Publication number Publication date
AU758114C (en) 2003-10-30
AR018670A1 (en) 2001-11-28
EE200000743A (en) 2002-10-15
SG111980A1 (en) 2005-06-29
PL198504B1 (en) 2008-06-30
TWI235152B (en) 2005-07-01
CA2333550A1 (en) 1999-12-16
NO20006255D0 (en) 2000-12-08
AU4436499A (en) 1999-12-30
PL345221A1 (en) 2001-12-03
EP1086087A1 (en) 2001-03-28
HUP0103819A2 (en) 2002-02-28
SK18182000A3 (en) 2001-08-06
IL139793A (en) 2006-10-31
MY126450A (en) 2006-10-31
NZ507713A (en) 2003-08-29
SG111981A1 (en) 2005-06-29
ZA200006173B (en) 2001-10-31
IL139793A0 (en) 2002-02-10
HRP990182A2 (en) 2000-02-29
BR9911523A (en) 2001-09-18
SG134977A1 (en) 2007-09-28
UA74324C2 (en) 2005-12-15
WO1999064405A1 (en) 1999-12-16
CN1307568A (en) 2001-08-08
JP2002517487A (en) 2002-06-18
HUP0103819A3 (en) 2003-05-28
AR077469A2 (en) 2011-08-31
EE05547B1 (en) 2012-06-15
AU758114B2 (en) 2003-03-13
AR077407A2 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
ATE341990T1 (en) SIGMIDOSCOPE
DE59902874D1 (en) BUCHSENKONTAKT
DE59901560D1 (en) RETROGRADER TIBIANAGEL
PT1119430E (en) STRAWBERRY
ID23761A (en) SUBSTITUTED TRISICLIC
EE200100135A (en) Crystalline forms of EtO2C-CH2- (R) Cgl-Aze-Pab-OH
ID24221A (en) PATRUM PLACE
ID27735A (en) ARILALKANOILPIRIDAZIN-ARILALKANOILPIRIDAZIN
EE05547B1 (en) Crystalline Efavirenz
ATE262513T1 (en) BENZOYLPYRIDAZINE
DE69714228D1 (en) CRYSTALLINE METALLOPHOSPHATE
ID23219A (en) SUBSTITUTED TRISICLIC
FI980222A0 (en) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
DE59901046D1 (en) Methylcyclotetradec-5-en-1-one
PT1102747E (en) OSANETANT CRYSTALLINE FORMS
DE59807217D1 (en) NADELLAGER
DE59808995D1 (en) endomicroscope
DE19842103B4 (en) Stanznietzuführung
DE59902088D1 (en) Achrathermer Reimager
FI980856A0 (en) Andningsskydd utrustad med en identifierare
ATE303996T1 (en) SUBSTITUTED ACYLAMINOPHENYL URACILES
DE59912188D1 (en) SUBSTITUTED PHENYLURACILE
PT1076660E (en) (4-BROMOPYRAZOL-3-YL) -BZZAZOLES
DE59901263D1 (en) SINGLE-GRADERS
FI980053A0 (en) Anordning Foer utformande av fiberbollar av laongstraeckta fibrer som foeljer med enluftstroem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application